SAFETY AND PHARMACOKINETICS OF ABI-H3733, A NOVEL 2nd GENERATION HBV CORE PROTEIN INHIBITOR: RESULTS FROM A PHASE 1a STUDY IN HEALTHY VOLUNTEERS

被引：0
|
作者：
Gane, Edward J. [1 ]
Schwabe, Christian [2 ]
Alves, Katia [3 ]
Evanchik, Marc [3 ]
Ma, Julie [3 ]
Zomorodi, Katie [3 ]
Knox, Steven J. [3 ]
Stamm, Luisa M. [3 ]
机构：
[1] Auckland City Hosp, Liver Transplant Unit, Auckland, New Zealand
[2] New Zealand Clin Res, Auckland, New Zealand
[3] Assembly Biosci Inc, San Francisco, CA USA
来源：
HEPATOLOGY | 2021年 / 74卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
842
引用
收藏
页码：516A / 516A
页数：1
相关论文
共 48 条
  • [21] OCE-205, A Novel, Selective Vasopressin Receptor Mixed Agonist-Antagonist: Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics from a Phase 1 Study in Healthy Volunteers
    Yu Bagger
    William R. Ravis
    Geoff Harris
    Stan Bukofzer
    Clinical Drug Investigation, 2023, 43 : 709 - 717
  • [22] Safety, Pharmacokinetics, and Pharmacodynamics Of SAN-300, a Novel Monoclonal Antibody Against Very Late Antigen-1: Results Of a Phase 1 Study In Healthy Volunteers and Patients With Active Rheumatoid Arthritis.
    Inderjeeth, Charles
    Redfern, Andrew
    Huang, Michael
    Hardiman, Yun
    Grant, Theresa
    Fritz, Lawrence C.
    Fuller, David
    Haughey, David
    Totoritis, Mark C.
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S610 - S610
  • [23] Final Results of a Phase 1b 28-Day Study of ABI-H0731, a Novel Core Inhibitor, in Non-Cirrhotic Viremic Subjects with Chronic Hepatitis B
    Yuen, Man-Fung
    Agarwal, Kosh
    Gane, Edward J.
    Schwabe, Christian
    Ahn, Sang Hoon
    Kim, Dong Joon
    Lim, Young-Suk
    Cheng, Wendy
    Sievert, William
    Visvanathan, Kumar
    Ruby, Eric
    Liaw, Sandy
    Yan, Ran
    Connelly, Emily
    Cai, Dawei
    Huang, Qi
    Colonno, Richard
    Lopatin, Uri A.
    HEPATOLOGY, 2018, 68 : 46A - 47A
  • [24] Single- and multiple-dose pharmacokinetics and safety of pimodivir, a novel, non-nucleoside polymerase basic protein 2 subunit inhibitor of the influenza A virus polymerase complex, and interaction with oseltamivir: a Phase 1 open-label study in healthy volunteers
    Deleu, Sofie
    Kakuda, Thomas N.
    Spittaels, Kurt
    Vercauteren, Jurgen J.
    Hillewaert, Vera
    Lwin, Amy
    Leopold, Lorant
    Hoetelmans, Richard M. W.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (11) : 2663 - 2672
  • [25] Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo-Controlled Studies in Healthy Volunteers (vol 5, pg 306, 2016)
    Erpenbeck, V. J.
    Vets, E.
    Gheyle, L.
    Osuntokun, W.
    Larbig, M.
    Neelakantham, S.
    Sandham, D.
    Dubois, G.
    Elbast, W.
    Goldsmith, P.
    Weiss, M.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020, 9 (07): : 889 - 890
  • [26] Safety, Pharmacokinetics and Anti-Viral Efficacy of Novel Core Protein Allosteric Modifier GLS4 in Patients with Chronic Hepatitis B: Interim Results from a 48 Weeks Phase 2a Study
    Zhang, Hong
    Zhu, Xiaoxue
    Chen, Hong
    Li, Xiaojiao
    Hu, Yue
    Wu, Min
    Li, Cuiyun
    Luo, Lin
    Zhang, Yingjun
    Ding, Hua Yan
    Niu, Junqi
    Liu, Yan
    He, Qingwei
    Chen, Yunfu
    Ren, Qingyun
    Gu, Baohua
    Jing, Li
    HEPATOLOGY, 2018, 68 (06) : 1454A - 1455A
  • [27] DA-1241, a Novel GPR119 Agonist: Data on Safety, Tolerability, and Pharmacokinetics (PK) from Part 1 of a Phase lb Multiple Ascending Dose (MAD) Study in Healthy Volunteers (HV)
    Kim, Mi-Kyung
    Lee, Dae Young
    Jeong, Jiyoon
    Grimm, Michael
    Franey, Bridgette B.
    Hompesch, Marcus
    DIABETES, 2021, 70
  • [28] Safety and efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid and CNS tumors: Results from a phase 1/2a study
    De La Fuente, Macarena Ines
    Ahnert, Jordi Rodon
    Yaeger, Rona
    Tsai, Frank Yung-Chin
    Janku, Filip
    Butowski, Nicholas A.
    Allen, Carl E.
    Ammakkanavar, Natraj Reddy
    Taylor, Jennie Webster
    Michelson, Glenn
    Kline, Irina
    Paz, Michael
    Tussay-Lindenberg, Alexia
    Wong, Kongming
    Shepherd, Stacie Peacock
    Jiang, Ping
    Sherman, Eric Jeffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [29] DA-1241 a novel GPR119 agonist: Data on safety, tolerability and pharmacokinetics (PK), from part 1 of a phase 1b multiple ascending dose (MAD) study in healthy volunteers (HV)
    Franey, B.
    Grimm, M.
    Lee, D.
    Jeong, J.
    Kim, M. -K.
    Hompesch, M.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 241 - 242
  • [30] Single and multiple dose pharmacokinetics and safety of ZSP1273, an RNA polymerase PB2 protein inhibitor of the influenza A virus: a phase 1 double-blind study in healthy subjects
    Hu, Yue
    Li, Haijun
    Wu, Min
    Zhang, Hong
    Ding, Yanhua
    Peng, Yun
    Li, Xiaojiao
    Yu, Zhenxiang
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2021, 30 (11) : 1159 - 1167
12345